Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -33.77% is 143% below its 5-year average of -13.90%, near the low end of its 5-year range (-33.77%–-3.17%).
35.92% below its 12-month average of -24.84%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.03%.
RETURN ON ASSETS (ROA)
-33.77%
RETURN ON ASSETS (ROA) AVG TTM
-24.84%
RETURN ON ASSETS (ROA) AVG 3Y
-18.48%
RETURN ON ASSETS (ROA) AVG 5Y
-13.90%
RETURN ON ASSETS (ROA) AVG 10Y
-19.53%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.92%
CURRENT VS 3Y AVG
-82.79%
CURRENT VS 5Y AVG
-142.95%
CURRENT VS 10Y AVG
-72.91%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-4.75%
vs the sector median at left
XBiotech Inc.
Market Cap
$66.16M
Return on Assets (ROA)
-33.77%
TTM Avg
-24.84%
3Y Avg
-18.48%
5Y Avg
-13.90%
Market Cap
$66.56M
Return on Assets (ROA)
-33.34%
TTM Avg
-56.30%
3Y Avg
-89.26%
5Y Avg
-70.59%
Market Cap
$67.02M
Return on Assets (ROA)
-87.09%
TTM Avg
-130.17%
3Y Avg
-272.35%
5Y Avg
-217.34%
Market Cap
$67.66M
Return on Assets (ROA)
-3.41%
TTM Avg
5.09%
3Y Avg
-8.30%
5Y Avg
-5.06%
Market Cap
$64.71M
Return on Assets (ROA)
-162.91%
TTM Avg
-58.42%
3Y Avg
-64.67%
5Y Avg
-61.98%
Market Cap
$63.58M
Return on Assets (ROA)
-39.17%
TTM Avg
-30.96%
3Y Avg
-31.81%
5Y Avg
-21.33%
Market Cap
$68.60M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$68.40M
Return on Assets (ROA)
-160.34%
TTM Avg
-132.74%
3Y Avg
-130.12%
5Y Avg
-105.91%
Market Cap
$63.19M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XBiotech Inc. (XBIT) | $66.16M | -33.77% | -24.84% | -18.48% | -13.90% |
| iBio, Inc. (IBIO)vs › | $66.56M | -33.34% | -56.30% | -89.26% | -70.59% |
| Cingulate Inc. (CING)vs › | $67.02M | -87.09% | -130.17% | -272.35% | -217.34% |
| Champions Oncology, Inc. (CSBR)vs › | $67.66M | -3.41% | 5.09% | -8.30% | -5.06% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.71M | -162.91% | -58.42% | -64.67% | -61.98% |
| Alps Group Inc (ALPS)vs › | $63.58M | -39.17% | -30.96% | -31.81% | -21.33% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | 35.31% | -14.11% | -23.46% | -20.68% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.40M | -160.34% | -132.74% | -130.12% | -105.91% |
| InterCure Ltd. (INCR)vs › | $63.19M | -5.05% | -7.03% | -4.31% | -4.67% |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.48M | 13.99% | -24.80% | -18.57% | -29.63% |
ROA
-33.8%
ROE
-35.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.34% |
| 2024-12-31 | -19.35% |
| 2023-12-31 | -10.84% |
| 2022-12-31 | -13.37% |
| 2021-12-31 | -6.33% |
| 2020-12-31 | -3.17% |
| 2019-12-31 | 81.85% |
| 2018-12-31 | -47.67% |
| 2017-12-31 | -52.64% |
| 2016-12-31 | -78.69% |
| 2015-12-31 | -34.28% |
| 2014-12-31 | -34.94% |
| 2013-12-31 | -89.65% |
| 2012-12-31 | -179.01% |
